Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimization of an immunotherapeutic protocol with poly(I,C)-LC.

J E Talmadge, D Hartmann

    Journal of Biological Response Modifiers
    |October 1, 1985
    PubMed
    Summary

    Optimizing biological response modifier (BRM) doses, not using maximum tolerated dose (MTD), enhances immunomodulation and therapeutic benefits in tumor models. This suggests improved clinical trial strategies for cancer immunotherapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Cutaneous Infections Caused by Pseudomonas aeruginosa. Clinical Presentation, Diagnosis and Treatment.

    Actas dermo-sifiliograficas·2026
    Same author

    Ex Vivo Confocal Laser Scanning Microscopy for Real-Time Pattern and Single-Cell Analysis in Inflammatory Skin Diseases.

    Experimental dermatology·2025
    Same author

    Precision at the Cutting Edge: Ex Vivo Confocal Microscopy for Perioperative Tumour Thickness Assessment in Melanoma.

    Experimental dermatology·2025
    Same author

    [Digital pathology using ex vivo confocal laser scanning microscopy].

    Dermatologie (Heidelberg, Germany)·2025
    Same author

    Incretin-responsive human pancreatic adipose tissue organoids: A functional model for fatty pancreas research.

    Molecular metabolism·2024
    Same author

    A literature review and expert consensus statement on diagnostics in suspected metal implant allergy.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2024

    Area of Science:

    • Immunotherapy
    • Cancer Research
    • Pharmacology

    Background:

    • Successful immunotherapeutic protocols need predictive tumor models and novel strategies.
    • Many biological response modifiers (BRMs) exhibit bell-shaped dose-response curves for immunomodulation and therapeutic activity.
    • High doses of BRMs, like poly(I,C)-LC, can be toxic, potentially limiting efficacy.

    Purpose of the Study:

    • To investigate the impact of optimal dosing protocols versus maximum tolerated dose (MTD) for BRMs in cancer treatment.
    • To evaluate the immunomodulatory and therapeutic effects of non-toxic BRM doses in tumor-bearing animal models.
    • To propose a shift in clinical trial design for immunotherapies.

    Main Methods:

    • Utilized tumor-bearing animal models to assess BRM efficacy.
    • Administered BRMs, including poly(I,C)-LC, using both MTD and optimized, non-toxic dose protocols.
    • Monitored immunomodulation and therapeutic activity in response to different dosing strategies.

    Main Results:

    • Non-toxic doses of BRMs, administered via optimal protocols, demonstrated significant therapeutic benefits in tumor-bearing animals.
    • Optimal protocols led to increased immunomodulation compared to MTD administration.
    • Bell-shaped response curves were confirmed for BRMs, highlighting dose-dependency.

    Conclusions:

    • Optimal immunomodulatory protocols, rather than MTD-based ones, may yield superior therapeutic outcomes in cancer treatment.
    • Phase II clinical trials could benefit from employing optimized BRM dosing strategies.
    • This research suggests a paradigm shift in designing immunotherapeutic regimens for enhanced patient response.

    Related Experiment Videos